



## FEP Medical Policy Manual

### FEP 2.04.136 Nutrient/Nutritional Panel Testing

**Annual Effective Policy Date: April 1, 2026**

**Original Policy Date: March 2024**

**Related Policies:**

- 2.04.23 - Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disorders
- 2.04.73 - Intracellular Micronutrient Analysis

## Nutrient/Nutritional Panel Testing

### Description

#### Description

Multimarker nutritional panel testing is proposed for patients with certain chronic conditions (eg, mood disorders, fibromyalgia, unexplained fatigue) as well as for healthy individuals seeking to optimize health and/or fitness.

#### OBJECTIVE

The objective of this evidence review is to determine whether nutrient/nutritional panel testing improves the net health outcome among individuals with mood disorders, fibromyalgia, or unexplained fatigue, or among healthy individuals seeking to optimize health and fitness.

#### POLICY STATEMENT

Nutrient/nutritional panel testing is considered **investigational** for all indications including but not limited to testing for nutritional deficiencies in individuals with mood disorders, fibromyalgia, or unexplained fatigue, and healthy individuals.

## POLICY GUIDELINES

None

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

## FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Nutrient/nutritional panel testing using urine and/or blood samples is offered (eg, NutrEval FMV and NutrEval Plasma by Genova Diagnostics; micronutrient testing by SpectraCell) under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

## RATIONALE

### Summary of Evidence

For individuals who have mood disorders, fibromyalgia, or unexplained fatigue, or healthy individuals who seek to optimize health and fitness who receive nutritional panel testing, the evidence includes several systematic reviews and randomized controlled trials (RCTs) on the association between a single condition and a single nutrient and on the treatment of specific conditions with nutritional supplements. Relevant outcomes are symptoms, change in disease status, and functional outcomes. Systematic reviews have found statistically significant associations between depression or fibromyalgia and levels of several nutrients; however, there is little evidence that nutrient supplementation for patients with depression improves health outcomes. An RCT has also found statistically significant associations between fatigue and levels of vitamin D. However, there is no direct evidence on the health benefits of nutritional panel testing for any condition, including testing healthy individuals, and no evidence that nutritional panel testing is superior to testing for individual nutrients for any condition. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest. No guidelines or statements were identified.

### U.S. Preventive Services Task Force Recommendations

The **U.S. Preventive Services Task Force** (USPSTF) has not addressed nutritional panel testing. The USPSTF has made several recommendations addressing screening for individual nutrients. The USPSTF concluded that there is insufficient evidence to recommend for or against screening for iron deficiency anemia in asymptomatic children, adolescents and pregnant women, as well as vitamin D deficiency in asymptomatic, nonpregnant adults.<sup>13,14,15</sup>

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

## REFERENCES

1. Genova Diagnostics. NutrEval FMV; <https://www.gdx.net/product/nutreval-fmv-nutritional-test-blood-urine>. Accessed November 7, 2025.
2. Genova Diagnostics. NutrEval Plasma; <https://www.gdx.net/product/nutreval-nutritional-test-plasma>. Accessed November 7, 2025.
3. SpectraCell Laboratories Micronutrient Test Panel. <https://www.spectracell.com/micronutrient-test>. Accessed November 7, 2025.
4. Petridou ET, Kousoulis AA, Michelakos T, et al. Folate and B12 serum levels in association with depression in the aged: a systematic review and meta-analysis. *Aging Ment Health*. Sep 2016; 20(9): 965-73. PMID 26055921
5. Cheungpasitporn W, Thongprayoon C, Mao MA, et al. Hypomagnesaemia linked to depression: a systematic review and meta-analysis. *Intern Med J*. Apr 2015; 45(4): 436-40. PMID 25827510
6. Swardfager W, Herrmann N, Mazereeuw G, et al. Zinc in depression: a meta-analysis. *Biol Psychiatry*. Dec 15 2013; 74(12): 872-8. PMID 23806573
7. Anglin RE, Samaan Z, Walter SD, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *Br J Psychiatry*. Feb 2013; 202: 100-7. PMID 23377209
8. Hsiao MY, Hung CY, Chang KV, et al. Is Serum Hypovitaminosis D Associated with Chronic Widespread Pain Including Fibromyalgia? A Meta-analysis of Observational Studies. *Pain Physician*. 2015; 18(5): E877-87. PMID 26431141
9. Daniel D, Pirota MV. Fibromyalgia--should we be testing and treating for vitamin D deficiency?. *Aust Fam Physician*. Sep 2011; 40(9): 712-6. PMID 21894281
10. Gowda U, Mutowo MP, Smith BJ, et al. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. *Nutrition*. Mar 2015; 31(3): 421-9. PMID 25701329
11. Taylor MJ, Carney S, Geddes J, et al. Folate for depressive disorders. *Cochrane Database Syst Rev*. 2003; 2003(2): CD003390. PMID 12804463
12. Nowak A, Boesch L, Andres E, et al. Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. *Medicine (Baltimore)*. Dec 2016; 95(52): e5353. PMID 28033244
13. U.S. Preventive Services Task Force (USPSTF). Iron Deficiency Anemia in Pregnant Women: Screening and Supplementation. 2024. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-pregnant-women-screening-and-supplementation>. Accessed November 7, 2025.
14. U.S. Preventive Services Task Force (USPSTF). Iron Deficiency Anemia: Screening. 2015; <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-young-children-screening#fullrecommendationstart>. Accessed November 7, 2025.
15. U.S. Preventive Services Task Force (USPSTF). Vitamin D Deficiency: Screening. 2021; <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-deficiency-screening>. Accessed November 7, 2025.

**POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:**

<b>Date</b>	<b>Action</b>	<b>Description</b>
December 2015	New policy	Considered investigational for all indications including but not limited to testing for nutritional deficiencies in patients with mood disorders, fibromyalgia, unexplained fatigue, and healthy individuals.
March 2018	Replace policy	Policy updated with a literature search through November 7, 2017; references 5, 7, and 10 added. Policy statement unchanged.
September 2019	Replace policy	Policy updated with a literature search through October 1, 2018; no references added. Policy statement unchanged.
March 2020	Replace policy	Policy updated with a literature review through October 14, 2019; no references added. Policy statement unchanged.
March 2021	Replace policy	Policy updated with a literature review through October 20, 2020; references added. Policy statement unchanged.
March 2022	Replace policy	Policy updated with literature review through October 19, 2021; no references added, reference to USPSTF vitamin D recommendation updated. Policy statement unchanged.
March 2023	Replace policy	Policy updated with literature review through October 19, 2022; reference added. Minor editorial refinements to policy statements; intent unchanged.
March 2024	Replace policy	Policy updated with literature review through October 23, 2023; no references added. Policy statement unchanged.
June 2025	Replace policy	Policy updated with literature review through October 16, 2024; no references added. Policy statement unchanged.
March 2026	Replace policy	Policy updated with literature review through November 10, 2025; no references added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.